Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05564637 · ClinicalTrials.gov registry record · Phase 2
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT05564637: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT05564637 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05564637, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out more about the drug treprostinil via inhaler and the mechanisms of why patients with pulmonary arterial hypertension related to Interstitial Lung disease (PAH-ILD) have limitations during exercise. The investigator is studying treprostinil's effect on patients with PAH-ILD during exercise and its effect on their quality of life after using it for 3 months.
Interventions
- DRUG Treprostinil
- DIAGNOSTIC_TEST Right Heart Catheterization (RHC) while exercising
- DIAGNOSTIC_TEST Optional Muscle Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05564637
The ClinicalTrials.gov registry entry for NCT05564637 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Treprostinil is the first listed.
NCT05564637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05564637 about?
NCT05564637 is a clinical study titled "A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension". The purpose of this research study is to find out more about the drug treprostinil via inhaler and the mechanisms of why patients with pulmonary arterial hypertension related to Interstitial Lung disease (PAH-ILD) have limitations during exercise. The investigator is studying treprostinil's effect o...
What is the current status of trial NCT05564637?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2023-03-13. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT05564637?
The interventions under investigation include: Treprostinil (DRUG), Right Heart Catheterization (RHC) while exercising (DIAGNOSTIC_TEST), Optional Muscle Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05564637?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.